1. Mendelian randomisation study of the effects of known and putative risk factors on pancreatic cancer
- Author
-
Manuel Gentiluomo, Luca Morelli, Ofure Obazee, Daniele Campa, Federico Canzian, Justo Lorenzo-Bermejo, and Ye Lu
- Subjects
Adult ,Male ,0301 basic medicine ,Oncology ,medicine.medical_specialty ,pancreatic cancer ,Type 2 diabetes ,Adenocarcinoma ,Polymorphism, Single Nucleotide ,Body Mass Index ,Helicobacter Infections ,03 medical and health sciences ,0302 clinical medicine ,genetic polymorphisms ,Pancreatic cancer ,Internal medicine ,Mendelian randomization ,Genetics ,medicine ,Humans ,Insulin ,risk factors ,Genetic Predisposition to Disease ,Obesity ,Genetics (clinical) ,Aged ,Genetic association ,business.industry ,Mendelian Randomization Analysis ,Middle Aged ,medicine.disease ,030104 developmental biology ,Diabetes Mellitus, Type 2 ,030220 oncology & carcinogenesis ,Cohort ,Female ,Observational study ,business ,Body mass index ,Carcinoma, Pancreatic Ductal ,Genome-Wide Association Study - Abstract
BackgroundObservational studies have reported multiple risk factors for pancreatic ductal adenocarcinoma (PDAC). Some are well established, like tobacco smoking, alcohol drinking, obesity and type 2 diabetes, whereas some others are putative, such as allergy and dietary factors. Identifying causal risk factors can help establishing those that can be targeted to contribute to prevent PDAC.ObjectiveWe sought to investigate the possible causal effects of established and putative factors on PDAC risk.MethodsWe conducted a two-sample Mendelian randomisation (MR) study using publicly available data for genetic variants associated with the factors of interest, and summary genetic data from genome-wide association studies of the Pancreatic Cancer Cohort Consortium (PanScan) and the Pancreatic Cancer Case-Control Consortium (PanC4), including in total 8769 cases and 7055 controls. Causality was assessed using inverse-variance weighted, MR-Egger regression and weighted median methods, complemented with sensitivity and radial MR analyses.ResultsWe found evidence for a causal effect of body mass index (BMI) on PDAC risk (OR 1.43, 95% CI 1.20 to 1.71, p=8.43×10−5). Fasting insulin (OR 2.84, 95% CI 1.23 to 6.56, p=0.01), low-density lipoprotein cholesterol (OR 1.16, 95% CI 1.02 to 1.32, p=0.03) and type 2 diabetes (OR 1.09, 95% CI 1.01 to 1.17, p=0.02) were also causally associated with PDAC risk. BMI showed both direct and fasting insulin-mediated causal effects.ConclusionWe found strong evidence that BMI is causally associated with PDAC risk, providing support that obesity management may be a potential prevention strategy for reducing pancreatic cancer risk while fasting insulin and type 2 diabetes showed a suggestive association that should be further investigated.
- Published
- 2020
- Full Text
- View/download PDF